

## Effects of lycopene, a carotenoid, on intrathymic T cell differentiation and peripheral CD4/CD8 ratio in a high mammary tumor strain of SHN retired mice

Takao Kobayashi, Koji Iijima,<sup>1</sup> Tadasu Mitamura, Kazuo Torizuka,<sup>1</sup> Jong-Chol Cyong<sup>1</sup> and Hiroshi Nagasawa

Experimental Animal Research Laboratory, Meiji University, Tama-ku, Kawasaki, 214-71, Japan.  
Tel: (+81) 44 934 7073; Fax: (+81) 44 934 7073. <sup>1</sup>Oriental Medicine Research Center of the Kitasato Institute, Minato-ku, Tokyo 108, Japan

We previously reported that lycopene, one of the carotenoids, significantly suppressed the development of spontaneous mammary tumors of mice and the contribution of lycopene to the maintenance of physical homeostasis was suggested. In this study, we investigated the effects of lycopene on the intrathymic and peripheral T cell subpopulation as immunoregulatory parameters. In tumorous control mice, inactivation of intrathymic T cell differentiation, an increase of the percentage of CD4<sup>+</sup>CD8<sup>-</sup> cells and a decrease of CD4<sup>+</sup>CD8<sup>+</sup> cells were observed. On the other hand, in the lycopene-treated mice, the abnormal intrathymic T cell differentiation was recovered and brought to non-tumorous levels. The peripheral CD4/CD8 ratio was partially augmented by lycopene treatment which resulted from an increased CD4<sup>+</sup> subpopulation. These observations suggest that one of the immunomodulating roles of lycopene is to normalize the change of intrathymic T cell differentiation caused by tumorigenesis.

**Key words:** Carotenoid, lycopene, mammary tumor, mice, T cell.

### Introduction

Recent studies indicated that  $\beta$ -carotene and carotenoids were effective in the prevention of several types of tumors.<sup>1,2</sup> We found that the administration of natural  $\beta$ -carotene-rich algae *Dunaliella bardawil* prevented spontaneous mammary tumorigenesis in mice.<sup>3,4</sup> Lycopene, one of the carotenoids, is considered to be superior to  $\beta$ -carotene in quenching the singlet oxygen<sup>5</sup> and further contributes to the same extent or even more than  $\beta$ -carotene to total carotenoids in human tissue.<sup>6</sup>

Previously, we found that chronic ingestion of lycopene markedly suppressed the development of spontaneous mammary tumors in mice and indica-

ted the possibility of the contribution of lycopene to the maintenance of physical homeostasis.<sup>7</sup>

There is accumulating evidence that carotenoids can enhance the immune response, including non-specific and specific immune functions and tumor immunity.<sup>8</sup> This tempted us to examine the effects of lycopene on intrathymic T cell differentiation and the peripheral T cell subpopulation as immunoregulatory parameters. This paper deals with this problem.

### Materials and methods

#### Animals and treatments

Retired female mice of a high mammary tumor strain of SHN/Mei<sup>9,10</sup> maintained in our laboratory were used. Throughout the experiments, the animals were kept in teflon cages (15 × 27 × 12 cm) with wood shavings (three or four each), maintained in a windowless animal room, which was air conditioned (21–22°C and 55–75% relative humidity) and artificially illuminated (14 h of light from 5:00 a.m. to 7:00 p.m.) and provided with tap water *ad libitum*. Each mouse was checked for palpable size ( $\geq 3$  mm) of mammary tumors every 7 days. Both tumorous and non-tumorous mice were divided into two groups, i.e. control and experimental. The control mice received AIN-76TM diet (Nihon-Nosan Kogyo KK, Yokohama, Japan). The experimental mice were given AIN-76TM diet supplemented with lycopene (Makhteshim Chemical Works, Beer-Sheva, Israel) at the concentration of  $5.0 \times 10^{-5}\%$ . Each diet, which was packed *in vacuo* and kept at  $-20^\circ\text{C}$ , was changed every day. After 10 days of treatment, mice were killed by decapitation under light ether anesthesia.

#### Preparation of lymphoid cell

At autopsy, blood was collected from the trunk and diluted twice with 10 U/ml of heparin/PBS(–). Thy-

---

This investigation was supported in part by Japan Keirin Association to KI, KT and J-CC, and the research fund of the special project from the Institute of Science and Technology, Meiji University to HN.

Correspondence to H. Nagasawa

**Table 1.** Body weight and weights of thymus and spleen in each group (mean  $\pm$  SEM)

Group	Body weight (g)	Thymus weight (mg/30 g body weight)	Spleen weight (mg/30 g body weight)
Non-tumorous			
control (6)	31.8 $\pm$ 0.7	30.3 $\pm$ 5.4	95.6 $\pm$ 7.0 <sup>a</sup>
experimental (5)	30.1 $\pm$ 0.7	25.5 $\pm$ 4.4	93.9 $\pm$ 7.4 <sup>a</sup>
Tumorous			
control (5)	31.6 $\pm$ 1.0	29.7 $\pm$ 1.9	108.9 $\pm$ 4.2 <sup>a</sup>
experimental (5)	31.7 $\pm$ 0.8	26.2 $\pm$ 3.6	87.2 $\pm$ 6.6 <sup>b</sup>

Number of estimates is given in parentheses.

<sup>a,b</sup>Values with different superscripts are different at  $p < 0.05$ .



mus and spleen were also immediately removed, weighed and pressed with slide glass in PBS(-). The cell suspension was passed through a #200 metal sieve and washed three times with PBS(-). Diluted blood and thymic and splenic cell suspensions were layered onto Ficoll-Conray solution (Immuno-Biological Laboratories, Fujioka, Japan) and centrifuged at 400 g for 30 min at room tem-

perature. The interface layer was collected and washed three times with PBS(-).



#### Flow cytometric analysis

Cells were incubated with 1  $\mu$ g/million cells of R-phycoerythrin (PE)-conjugated anti-mouse CD4 and fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD8a rat IgG monoclonal antibody (Phar-

#### Non-tumorous



#### Tumorous



Control

Experimental

**Figure 1.** Two-color fluorescence histograms of the expression of CD4 and CD8 markers on thymocytes from mice of each group. Staining and flow cytometric analysis were performed as detailed in Materials and methods. Numbers in histograms are the percentage of each subpopulation.

**Table 2.** Percentage of thymocytes expressing surface antigenic markers in each group (mean  $\pm$  SEM)

Group	CD4 <sup>+</sup> CD8 <sup>-</sup>	CD4 <sup>+</sup> CD8 <sup>+</sup>	CD4 <sup>-</sup> CD8 <sup>-</sup>	CD4 <sup>-</sup> CD8 <sup>+</sup>
Non-tumorous				
control (5)	27.7 $\pm$ 4.7 <sup>a</sup>	58.5 $\pm$ 7.4	3.2 $\pm$ 0.6 <sup>a</sup>	10.6 $\pm$ 2.1
experimental (5)	35.2 $\pm$ 8.9 <sup>a,b</sup>	54.0 $\pm$ 11.9	1.2 $\pm$ 0.5 <sup>b</sup>	9.4 $\pm$ 2.4
Tumorous				
control (5)	48.7 $\pm$ 7.2 <sup>b</sup>	37.4 $\pm$ 8.9	2.2 $\pm$ 0.3 <sup>a,b</sup>	11.8 $\pm$ 1.5
experimental (5)	26.1 $\pm$ 2.2 <sup>a</sup>	63.2 $\pm$ 2.1	1.5 $\pm$ 0.3 <sup>a,b</sup>	9.4 $\pm$ 1.1

Number of estimates is given in parentheses.

<sup>a,b</sup>Values with different superscripts are different at  $p < 0.05$ .

**Table 3.** Percentage of splenic lymphocytes expressing surface antigenic markers and CD4/CD8 ratio in spleen of each group (mean  $\pm$  SEM)

Group	CD4 <sup>+</sup> CD8 <sup>-</sup>	CD4 <sup>-</sup> CD8 <sup>+</sup>	CD4/CD8
Non-tumorous			
control (6)	33.2 $\pm$ 1.4	14.7 $\pm$ 0.8	2.3 $\pm$ 0.1 <sup>a</sup>
experimental (5)	39.8 $\pm$ 3.6	14.0 $\pm$ 1.1	3.2 $\pm$ 0.3 <sup>b</sup>
Tumorous			
control (5)	38.6 $\pm$ 3.1	13.1 $\pm$ 1.0	3.0 $\pm$ 0.2 <sup>a,b</sup>
experimental (5)	38.2 $\pm$ 3.1	12.6 $\pm$ 0.5	3.1 $\pm$ 0.4 <sup>a,b</sup>

Number of estimates is given in parentheses.

<sup>a,b</sup>Values with different superscripts are different at  $p < 0.05$ .

**Table 4.** Percentage of peripheral blood lymphocytes expressing surface antigenic markers and CD4/CD8 ratio in each group (mean  $\pm$  SEM)

Group	CD4 <sup>+</sup> CD8 <sup>-</sup>	CD4 <sup>-</sup> CD8 <sup>+</sup>	CD4/CD8
Non-tumorous			
control (6)	55.9 $\pm$ 1.4	22.9 $\pm$ 1.8	2.5 $\pm$ 0.2
experimental (5)	63.3 $\pm$ 1.6	21.9 $\pm$ 2.0	3.0 $\pm$ 0.3
Tumorous			
control (5)	58.0 $\pm$ 2.5	22.3 $\pm$ 1.8	2.7 $\pm$ 0.3
experimental (5)	64.8 $\pm$ 1.9	22.2 $\pm$ 1.6	3.0 $\pm$ 0.3

Number of estimates is given in parentheses.

Mingen, San Diego, CA) for 1 h at 4°C. Stained cells were washed three times with PBS(-) and analyzed by an EPICS Elite flow cytometer (Coulter Cytometry, Hialeah, FL). A fluorescence histogram of at least 5000 counts was collected each sample.

### Statistics

Data in each parameter were analyzed by the multiple range test to evaluate the statistical significance of difference.

### Results

Lycopene showed little effect on body weight and weights of thymus and spleen in non-tumorous mice. However, in tumorous mice, spleen weight

of the experimental group was significantly smaller than that of the control (Table 1).

As shown in Figure 1 and Table 2, there were little differences in the intrathymic T cell subpopulations between the control and the experimental groups of non-tumorous mice, except the CD4<sup>-</sup>CD8<sup>-</sup> proportion, which was significantly higher in the former. In tumorous mice, the percentages of CD4<sup>+</sup>CD8<sup>-</sup> cells and CD4<sup>+</sup>CD8<sup>+</sup> cells in the experimental group were apparently lower and higher, respectively, than those in the control. In general, the proportions of the intrathymic T cell subpopulation of the tumorous mice were maintained at the levels of non-tumorous mice by lycopene treatment.

In non-tumorous mice, the CD4/CD8 ratio in splenic lymphocyte was significantly higher in the experimental group than in the control. The ratio was increased in the control of the tumorous animals; however, it was little changed in the experimental group (Table 3).

The CD4/CD8 ratio in the peripheral blood lymphocytes increased in the experimental group more than in the control, in the non-tumorous mice, but the difference was not significant (Table 4).

### Discussion

It is well known that carotenoids enhance the immune function. These include T and B lymphocyte proliferation, the induction of specific effector cells capable of killing tumor cells, and the secretion of factors required for communication between immunologically competent cells.<sup>8</sup> Lycopene, one of the carotenoids, has a marked anti-mammary tumor potential<sup>7</sup> and thus we examined the effect of lycopene on T cell differentiation.

Inactivation of intrathymic T cell differentiation was observed by malignancies.<sup>11,12</sup> The studies using the mice transplanted hepatoma MH134 cells<sup>11</sup> and mammary adenocarcinoma D1-DMBA-3 cells<sup>12</sup> revealed an increase and a decrease of

CD4<sup>+</sup>CD8<sup>-</sup> cells and CD4<sup>+</sup>CD8<sup>+</sup> cells, respectively. Quite similarly, in the present study, CD4<sup>+</sup>CD8<sup>-</sup> and CD4<sup>+</sup>CD8<sup>+</sup> cells were elevated and decreased, respectively, in mice developing spontaneous mammary tumors. On the other hand, lycopene treatment for 10 days recovered the proportions of CD4<sup>+</sup>CD8<sup>-</sup> and CD4<sup>+</sup>CD8<sup>+</sup> cells to those in the thymus of non-tumorous mice.

The peripheral CD4/CD8 ratio increased in the lycopene-treated non-tumorous mice, whereas it did not in the tumorous mice. In all groups, the proportions of CD8<sup>+</sup> cells were constant and thus an increase of the CD4/CD8 ratio is due to an increase in the proportion of the CD4<sup>+</sup> cells. It has been reported that  $\beta$ -carotene supplementation increased the number of T helper (CD4<sup>+</sup>) cells.<sup>13</sup> CD4 antigen is expressed on CD8<sup>-</sup> cells in the peripheral tissue and is commonly used as a convenient marker for helper T cells.<sup>14</sup> Helper CD4<sup>+</sup> T cells are known to release multiple cytokines which may be essential for the functional activation of human tumor-reactive effector cells.<sup>15</sup>

All observations suggest that lycopene enhances the immunoresponse by increasing helper T cells and that one of the immunomodulating actions of lycopene is to normalize the change of intrathymic T cell differentiation caused by tumorigenesis.

## References

1. van Poppel G. Carotenoids and cancer: an update with emphasis on human intervention studies. *Eur J Cancer* 1993; **29**: 1335-44.
2. Bendich A, Olson JA. Biological actions of carotenoids. *FASEB J* 1989; **3**: 1927-32.
3. Nagasawa H, Konishi R, Sensui N, et al. Inhibition by beta-carotene-rich algae *Dunaliella* of spontaneous mammary tumorigenesis in mice. *Anticancer Res* 1989; **9**: 71-6.
4. Nagasawa H, Fujii Y, Kageyama Y, et al. Suppression by beta-carotene-rich algae *Dunaliella bardawil* of the progression, but not the development, of spontaneous mammary tumors in SHN virgin mice. *Anticancer Res* 1991; **11**: 713-8.
5. Conn PF, Schalch W, Truscott TG. The singlet oxygen and carotenoid interaction. *J Photochem Photobiol* 1991; **11**: 41-7.
6. Parker RS. Carotenoids in human blood and tissues. *J Nutr* 1989; **119**: 101-4.
7. Nagasawa H, Mitamura T, Sakamoto S. Effects of lycopene on spontaneous mammary tumor development in SHN virgin mice. *Anticancer Res* 1995; **15**: 1173-8.
8. Bendich A. Carotenoids and the immune response. *J Nutr* 1989; **119**: 112-5.
9. Nagasawa H, Yanai R, Taniguchi H, et al. Two-way selection of a basal stock of Swiss albino mice for mammary tumorigenesis. Establishment of two new strains (SHN and SLN). *J Natl Cancer Inst* 1976; **52**: 425-30.
10. Staats J. Standardized nomenclature for inbred strains of mice: 8th listing. *Cancer Res* 1985; **45**: 945-77.
11. Seki S, Abo T, Sugiura K, et al. Reciprocal T cell response in the liver and thymus of mice injected with syngeneic tumor cells. *Cell Immunol* 1991; **137**: 46-60.
12. Fu Y, Paul RD, Wang Y, et al. Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas. *J Immunol* 1989; **143**: 4300-7.
13. Alexander M, Newmark H, Miller RG. Oral beta-carotene can increase the number of OKT4<sup>+</sup> cells in human blood. *Immunol Lett* 1985; **9**: 221-4.
14. Dialynas DP, Wilde DB, Marrack P, et al. Characterization of murine antigen determinant designated by L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. *Immunol Rev* 1983; **74**: 29-56.
15. Ioannides CG, Whiteside TL. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. *Clin Immunol Immunopathol* 1993; **66**: 91-106.

(Received 26 September 1995; accepted 26 October 1995)